Individual responses to retatrutide vary based on genetics, metabolic health, diet, exercise, stress, sleep, and other factors
10.1007/s11695-019-04248-x 126
From there, the retatrutide protocol expands endpoints beyond glucose, insulin, and glucagon to include lipids, appetite hormones, and calorimetry
These could change: FDA approval of retatrutide for obesity or diabetes would not change drug testing status, because the drug is not controlled
Antioxidants help to counteract free radicals and protect the body from their damaging effects
2,3 This project will extend the literature through an exploration of weight trajectories after cessation of long-term GLP-1 RA therapy and specifically seeks to answer the question: is there a duration of treatment with GLP-1 RA therapy after which weight loss is durable